Skip to main content
SpringerLink
Log in

Cognitive Enhancers in Alzheimer’s Disease

  • Chapter
Drug Studies in the Elderly

Abstract

Cognitive enhancers are compounds that have been purported to improve memory. Several drugs from various classes have been investigated clinically in the elderly population with different types of dementia. It is important to clarify that the dose-response relationships with these agents in the elderly population are almost nonexistent. This difficulty associated with the clinical trials in dementia patients is primarily due to problems related to quantification of the drug effect, as neuropsychological assessments have a large degree of associated measurement error. Pharmacokinetic and dynamic studies with these drugs have been few. Therefore, rather than choosing to discuss kinetics, as expected from the contributions in this part, we have decided to address methodological issues that pertain to all agents being evaluated in the elderly with some form of dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alzheimer A: Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie. 1907; 64: 1460–1480.

    Google Scholar 

  2. Constantinidis J: Is Alzheimer’s disease a major form of senile dementia? Clinical, anatomical, and genetic data, in Katzman R, Terry RD, Bick KL (eds): Alzheimer’s Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, vol 7, pp 15–25.

    Google Scholar 

  3. Roth M: Diagnosis of senile and related forms of dementia, in Katzman R, Terry RD, Bick KL (eds): Alzheimer’s Disease: Senile Dementia and Related Disorders. New York, Raven Press, 1978, vol 7, pp 71–85.

    Google Scholar 

  4. Petrie WM and Ban TA: Drugs in geropsychiatry. PsychopharmacolBull 1978; 14: 7–19.

    PubMed  CAS  Google Scholar 

  5. Salzman C: Stimulants in the elderly, in Raskin A, Robinson DS, Levine J (eds): Age and the Pharmacology of Psychoactive Drugs. New York, Elsevier North Holland Inc, 1981, pp 171–180.

    Google Scholar 

  6. Reding MJ, Young R, DiPonte P: Amitriptyline in Alzheimer’s disease. Neurology 1983; 33: 522–523.

    PubMed  CAS  Google Scholar 

  7. Cutler NR, Narang PK: Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. Psychiatr Clin North Am 1984; 7: 1–17.

    Google Scholar 

  8. Hollister LE, Yesavage J: Ergoloid mesylates for senile dementias: Unanswered questions. Ann Intern Med 1984; 100: 894–898.

    PubMed  CAS  Google Scholar 

  9. Van Loveren-Huyben CMS, Engelaan HFW, Hermans MBM, Van der Born JA, Leering C, Munnichs JMA: Doubleblind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc 1984; 32: 584–588.

    PubMed  Google Scholar 

  10. Epstein LJ: Anxiolytics, antidepressants, and neuroleptic patients, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 1517–1523.

    Google Scholar 

  11. Coyle JT, Price DL, DeLong MR: Alzheimer’s disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190.

    Article  PubMed  CAS  Google Scholar 

  12. Terry RD, Peck A, Deteresa R, Schechter R, Horoupian DS: Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–192.

    Article  PubMed  CAS  Google Scholar 

  13. Terry RD, Davies P: Some morphologic and biochemical aspects of Alzheimer’s disease, in Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G (eds): Aging of the Brain. New York, Raven Press, 1983; vol 22, pp 47–59.

    Google Scholar 

  14. Carlsson A, Adolfsson R, Aquilonius SM, et al: Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism, in Goldstein M, Calne DB, Lieberman A, Thorner MO (eds): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. New York, Raven Press, 1980, pp 295–314.

    Google Scholar 

  15. Tomlinson BE, Blessed G, Roth M: Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205–242.

    Article  PubMed  CAS  Google Scholar 

  16. Yamamoto T, Hirano A: Nucleus raphe dorsalis in Alzhemer’s disease: Neurofibrillary tangles and loss of large cortical neurons. Ann Neurol 1985; 17: 573–77.

    Article  PubMed  CAS  Google Scholar 

  17. Gottfries OG, Adolfsson R, Aquilonius SM: Biochemical changes in dementia disorders of Alzheimer’s type (AD/SDAT). Neurobiol Aging 1983; 4: 261–271.

    Article  PubMed  CAS  Google Scholar 

  18. Rossor MN: Neurotransmitters in CNS disease: Dementia. Lancet 1982; 2: 200–204.

    Google Scholar 

  19. Iwangoff P, Armbruster R, Enz A, Meier-Ruge W, Sandoz P: Glycolytic enzymes from human autoptic brain cortex: Normally aged and demented cases, in Roberts PJ (ed): Biochemistry of Dementia. London and New York, John Wiley Sons, 1980, pp 258–262.

    Google Scholar 

  20. Iwangoff P, Reichlmeier K, Enz A, Meier-Ruge W: Neurochemical findings in physiological aging of the brain. Interdiscipl Topics Gerontol 1979; 15: 13–33.

    CAS  Google Scholar 

  21. Perry EK, Perry RH: The cholinergic system in Alzheimer’s disease, in Roberts PJ (ed): Biochemistry of Dementia. New York, John Wiley Sons, 1980, pp 135–183.

    Google Scholar 

  22. Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–417.

    Article  PubMed  CAS  Google Scholar 

  23. Brinkman SD, Gershon S: Measurement of cholinergic drug effects on memory in Alzheimer’s disease. Neurobiol Aging 1983; 4: 261–271.

    Article  Google Scholar 

  24. Christie JE, Shering A, Ferguson J, Glen AIM: Physostigmine and arecholine: effects of intravenous infusion in Alzheimer presenile dementia. BrJ Psychiatry 1981; 138: 46–50.

    Article  CAS  Google Scholar 

  25. Wettstein A, Spiegel R, Koppel-Hefti A: Therapeutic trial with the muscarinic agonist RS-86 in patients with senile dementia of Alzheimer type. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Congress, Florence, Italy, June 18–23, 1983, pp 983.

    Google Scholar 

  26. Bruno G, Mohr E, Gillespie MM, Fedio P, Chase TN: RS-86 therapy of Alzheimer’s disease. Neurology 1985; 35 (suppl 1): 265.

    Google Scholar 

  27. Zornetzer SF: Neurotransmitter modulation and memory: A new neuropharmacological phrenology? in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 637–649.

    Google Scholar 

  28. Jellinger K, Flament H, Riederer P, Schmid H, Ambrogi L: Levodopa in the treatment of (pre) senile dementia. Mech Aging Dev 1980; 14: 253–264.

    Article  PubMed  CAS  Google Scholar 

  29. Ferris SH, Reisberg B, Friedman E: Combination cholinepiracetam treatment of senile dementia. Psychopharmacol Bull 1982; 18: 94.

    Google Scholar 

  30. Cutler NR, Haxby J, Kay AD, et al: Evaluation of zimelidine in alzheimer’s disease: cognitive and biochemical measures. Arch Neurol 1985; 42: 744–748.

    Article  PubMed  CAS  Google Scholar 

  31. Davies P, Katzman R, Terry RD: Reduced somatostatinlike immunoreactivity in cerebral cortex from cases of Alzheimer’s disease and Alzheimer senile dementia. Nature 1980; 288: 279–280.

    Article  PubMed  CAS  Google Scholar 

  32. Rossor MN, Emson PC, Mountjoy CQ, Roth M, Iversen LL: Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer’s type. Neurosci Lett 1980; 20: 373–377.

    Article  PubMed  CAS  Google Scholar 

  33. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martia JB: Reduced numbers of somatostatin receptors in cerebral cortex in Alzheimer’s disease. Science 1985; 229: 289–291.

    Article  PubMed  CAS  Google Scholar 

  34. Delfs JR, Zhy CH, Dichter MA: Coexistence of acetylcholinesterase and somatostatinimmunoreactivity in neurons cultured from rat cerebrum. Science 1984; 223: 61–63.

    Article  PubMed  CAS  Google Scholar 

  35. Ferris SH: Neuropeptides in the treatment of Alzheimer’s disease, in Reisberg B (ed): Alzheimer’s Disease. New York, The Free Press, 1983, pp 369–373.

    Google Scholar 

  36. Veber DF, Saperstein R, Nutt RF, et al: A super active cyclic hexapeptide analog of somatostatin. Life Sci 1984; 314: 1371–1378.

    Article  Google Scholar 

  37. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State, a practical method for grading the cognitive state of patients for the clinical. J Psychiatr Res 1975; 12: 189–198.

    Article  PubMed  CAS  Google Scholar 

  38. Cutler NR, Haxby JV, Narang PK, May C, Burg C, Reines SA: Evaluation of an analogue of somatostatin (L-363,586) in Alzheimer’s disease. N Engl J Med 1985; 312: 725.

    PubMed  CAS  Google Scholar 

  39. Kastin AJ, Olson GA, Sandman CA: Possible role of peptides in senile dementia, in: Crook T, Gerson S (eds): Strategies for the Development of an Effective Treatment for Senile Dementia. New Canaan, CT, Mark Powley Associates, 1981, pp 139–152.

    Google Scholar 

  40. Reisberg B, Ferris SH, Anand R: Effects of naloxone in senile dementia: a double blind trial. N Engl J Med 1983; 308: 721–722.

    Article  PubMed  CAS  Google Scholar 

  41. Blass JP, Reding MJ, Drachman E: Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer’s disease. N Engl J Med 1983; 309: 556.

    Article  Google Scholar 

  42. Bjorklund A, Gage FH, Schmidt RH, Stenevi U, Dunnet SB: Intracerebral grafting of neuronal cell suspensions VII. Recovery of choline acetyltransferase activity and acetylcholine synthesis in the denervated hippocampus reinnervated by septal suspension implants. Acta Physiol Scand 1983; (suppl 522 ): 59–66.

    Google Scholar 

  43. Rossor MN, Iverson LL, Reynolds GP, Mountjoy CQ, Roth M: Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med 1984; 288: 961–964.

    Article  CAS  Google Scholar 

  44. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811.

    Article  PubMed  CAS  Google Scholar 

  45. Mattis S: Mental status examination for organic mental syndrome in the elderly patient, in Bellak L, Katasu T (eds): Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, Grune Stratton, 1976, vol 7, pp 77–121.

    Google Scholar 

  46. Thal LJ,Fuld PA, Masur DM, Sharpless NS: Oral physostigmine and lecithin improve memory in Alzheimer’s disease. Ann Neurol 1983; 13:491–495.

    Article  PubMed  CAS  Google Scholar 

  47. Wettstein A: No effect from doubleblind trial of physostigmine and lecithin in Alzheimer’s disease. Ann Neurol 1983; 13: 210–212.

    Article  PubMed  CAS  Google Scholar 

  48. Wechsler D: A standardized memory scale for clinical use. J Psychol 1945; 19: 87–95.

    Article  Google Scholar 

  49. Benton AC: The Revised Visual Retention Test, New York, Psychological Corporation, 1974.

    Google Scholar 

  50. Benson DF: Aphasia, in Heilman EM, Valenstein E (eds): Clinical Neuropsychology. New York, Oxford University Press, 1979, pp 22–58.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatrics, Cedars-Sinai Medical Center, University of California-Los Angeles School of Medicine, Los Angeles, California, 90048, USA

    Neal R. Cutler

  2. Clinical Pharmacokinetics Research Laboratory, Pharmacy Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, 20892, USA

    Prem K. Narang

Authors
  1. Neal R. Cutler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prem K. Narang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Geriatrics Cedars-Sinai Medical Center, University of California-Los Angeles School of Medicine, 90048, Los Angeles, California, USA

    Neal R. Cutler M.D. (Director) (Director)

  2. Clinical Pharmacokinetics Research Laboratory Pharmacy Department Clinical Center, National Institutes of Health, 20892, Bethesda, Maryland, USA

    Prem K. Narang Ph.D. (Supervisor) (Supervisor)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Plenum Publishing Corporation

About this chapter

Cite this chapter

Cutler, N.R., Narang, P.K. (1986). Cognitive Enhancers in Alzheimer’s Disease. In: Cutler, N.R., Narang, P.K. (eds) Drug Studies in the Elderly. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1253-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-1253-6_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-1255-0

  • Online ISBN: 978-1-4684-1253-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation